Related Links
Statistics
| Number of Journals | 8 |
| Number of Issues | 52 |
| Number of Articles | 391 |
| Article View | 133,916 |
| PDF Download | 93,184 |
The Impact of Eptifibatide on Midterm Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention, A Retrospective Cohort Study | ||
| Advances in Pharmacology and Therapeutics Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 30 November 2025 | ||
| Document Type: retrospective study | ||
| Authors | ||
| Hamid Alian* ; Abbas Andishmand | ||
| Yazd Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | ||
| Abstract | ||
| Background: Primary percutaneous coronary intervention (PCI) is the standard reperfusion strategy for ST-elevation myocardial infarction (STEMI). Eptifibatide, a glycoprotein IIb/IIIa inhibitor, is used during primary PCI to prevent ischemic complications. However, the clinical effectiveness of eptifibatide remains uncertain. This study aimed to compare the rates of cardiac death, recurrent myocardial infarction (MI), or target vessel revascularization (TVR) at 12 months between patients who received eptifibatide and those who did not. Methods: A retrospective cohort study was conducted on 268 STEMI patients who underwent primary PCI. The patients were divided into two groups: those who received eptifibatide (n=134) and those who did not (n=134). The primary endpoint was a composite of cardiac death, recurrent myocardial infarction, and TVR at 12 months. Secondary endpoints included the individual components of the primary endpoint and the occurrence of in-hospital major bleeding. Results: The patients who received eptifibatide had a lower rate of major adverse cardiovascular events (MACEs) at 12 months compared to those who did not (11.2% vs 26.9%, p=0.001). Eptifibatide use was associated with lower rates of death (3% vs 11.2%, p=0.008), while rates of TVR (3.7% vs 8.2%, p=0.098) and recurrent MI (4.5% vs 7.5%, p=0.220) were not significantly different between the groups. The incidence of in-hospital major bleeding was not statistically significant (10.6% vs 4.5%, p=0.156). The comparison between the two groups revealed a statistically significant lower odds ratio of cardiac death and composite major adverse cardiovascular events in patients who received eptifibatide (OR 0.24, 95% CI: 0.08-0.76, p=0.015 and OR 0.34, 95% CI: 0.18-0.66, p=0.001, respectively). Conclusion: In STEMI patients undergoing primary PCI, the administration of eptifibatide was associated with lower rates of death and MACE at 12 months without an increase in in-hospital major bleeding. The use of eptifibatide during primary PCI may improve mid-term outcomes. | ||
| Keywords | ||
| eptifibatide; primary PCI STEMI; cardiac death bleeding; TVR; recurrent MI; MACE | ||
|
Statistics Article View: 4 |
||